PEPTIME Energy Caffeine Tablets Recalled for cGMP Deviations
Ultra Seal Corporation is voluntarily recalling PEPTIME Energy (caffeine 350mg) tablets due to cGMP (current good manufacturing practice) deviations. The recall affects 113,040 packets and 7,132 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving manufacturing practice deviations (cGMP violations). The source text does not report any illnesses, injuries, or deaths associated with the product, and the hazard is related to compliance with manufacturing standards rather than a direct safety threat. Per the rubric, Class II recalls without reported harm typically fall in the Moderate range.
Plain-English summary
Ultra Seal Corporation is voluntarily recalling PEPTIME Energy (caffeine 350mg) tablets packaged in 6-count packets (Lot #19E032) and 100-count bottles (Lot #19E033). The product is marketed by DMD Pharmaceuticals, A Division of Dickery Consumer Products, Inc., based in Noblesville, Indiana.
The recall was initiated due to cGMP (current good manufacturing practice) deviations in the manufacturing process. The affected products were distributed nationwide within the United States.
Consumers who have purchased PEPTIME Energy tablets should stop using the product. The FDA classified this as a Class II recall. The recall was initiated on January 24, 2022, and terminated on October 16, 2023.
The recalled product
- Product
- PEPTIME Energy (caffeine 350mg) tablets, packaged in a) 6 count packets and b) 100-count bottles, Marketed by: DMD Pharmaceuticals, A Division of Dickery Consumer Products, Inc., Noblesville, IN 46060.
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug — Supplement / OTC
- Hazard
- cgmp-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: a)19E032
- b)19E033
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27